Contrast makers cut patent deal
Epix Medical has granted Bracco Imaging a worldwide, nonexclusive, royalty-bearing license for the use of certain patents. The $10 million deal covers patents related to Bracco’s Multihance, which is used to image the liver and central nervous
Epix Medical has granted Bracco Imaging a worldwide, nonexclusive, royalty-bearing license for the use of certain patents. The $10 million deal covers patents related to Bracco’s Multihance, which is used to image the liver and central nervous system. In May 2000, Epix granted Schering a worldwide, nonexclusive, royalty-bearing license for the sale of Eovist, an investigational MRI contrast agent for liver imaging. The patents are owned by the Massachusetts General Hospital and licensed exclusively to Epix, which will receive upfront payments made up of a license fee, royalties on past sales, prepayment of future royalties, and a contingent license fee based on marketing approval of Multihance in the U.S.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
